SCHEMBL5210280

SCHEMBL5210280

COC(=O)CN(C(=O)OC(C)(C)C)c1ccc(NC(=O)OCc2ccccc2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.48
TP53 P04637 2/20 0.46
MAPT P10636 2/20 0.46
KDM1A O60341 2/20 0.45
MAOA P21397 2/20 0.45
MAOB P27338 2/20 0.45
SMN1; SMN2 Q16637 4/20 0.44
NPC1 O15118 3/20 0.44
RAB9A P51151 3/20 0.44
MLYCD O95822 1/20 0.44
ROCK2 O75116 1/20 0.44
RCOR1 Q9UKL0 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
MGLL Q99685 1/20 0.44
SYK P43405 1/20 0.43
ALDH1A1 P00352 2/20 0.42
PDE3B Q13370 1/20 0.42
PDE3A Q14432 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210956 0.92 POLB (0.49) POLBTP53MAPTKDM1AMAOA
SCHEMBL4832460 0.84 ALDH1A1 (0.56) MAPTSMN1; SMN2NPC1RAB9AMLYCD
SCHEMBL2574961 0.82 ALDH1A1 (0.61) MAPTMAOBSMN1; SMN2NPC1RAB9A
SCHEMBL6743562 0.82 TP53 (0.50) POLBTP53MAPTKDM1AMAOA
SCHEMBL7043026 0.81 POLB (0.62) POLBTP53MAPTKDM1AMAOA
SCHEMBL6295798 0.81 MLYCD (0.48) TP53SMN1; SMN2MLYCDMEN1KMT2A
SCHEMBL8960656 0.80 LMNA (0.44) MAPTSMN1; SMN2MLYCDL3MBTL1SYK
SCHEMBL4840386 0.80 SMN1; SMN2 (0.44) MAPTSMN1; SMN2MLYCDMEN1KMT2A
SCHEMBL5712257 0.80 POLB (0.47) POLBTP53MAPTKDM1AMAOA
SCHEMBL16207467 0.78 ABCB1 (0.50) MAPTSMN1; SMN2MLYCDKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1240154-B1 SERINE PROTEASE INHIBITORS TULARIK LTD (GB) 2007-02-28 EP disclosed
US-7157585-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2007-01-02 US disclosed
US-20050215587-A1 Serine protease inhibitors LIVELY SARAH E 2005-09-29 US disclosed
US-6916957-B2 Serine protease inhibitors TULARIK LIMITED (GB) 2005-07-12 US disclosed
US-20030018059-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050215587-A1 Serine protease inhibitors PRSS1, TPSAB1, CMA1 POLB 4675/4885TP53 3136/4885MAPT 4112/4885
US-20030018059-A1 Serine protease inhibitors TPSAB1, PRSS1, SERPINB1 POLB 4755/4885TP53 3993/4885MAPT 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.